BACKGROUND: Clinical testing for BRCA1/2 has been available since 1996. Interest in testing in the research and hypothetical situations has been consistently high, but there have been limited reports on its clinical utilization. METHODS: This is a retrospective study of BRCA1/2 test utilization by high-risk patients who were seen at the Johns Hopkins Breast and Ovarian Surveillance Service. RESULTS: Between February 1996 and December 1999, 258 families who had at least a 10% chance of carrying a BRCA1/2 mutation were offered genetic testing. Of these, 26 families seen between February 1996 and October 1996 had access to free testing. Overall, 68 of 258 (26%) underwent genetic testing. Educational level, number of children or daughters, breast carcinoma screening behavior, smoking and drinking behavior, perceived risk of breast carcinoma, and family history was not associated with test utilization. Eligibility for free testing, prior history of breast or ovarian carcinoma, Ashkenazi Jewish versus non-Ashkenazi Jewish heritage, genetic risk category, and age category were associated with test utilization, and in multivariate analysis, the first three remained statistically significant factors associated with genetic testing. Only 26% of the 50 patients who did not have access to free testing sought insurance reimbursement, of which greater than 50% (7 of 13) had a prior diagnosis of breast or ovarian carcinoma. CONCLUSIONS: The actual utilization of BRCA1/2 genetic testing in a clinical setting is lower than in the research and hypothetical settings. Potential obstacles include cost, fear of insurance discrimination, and need to involve an affected family member in the testing process. Copyright 2002 American Cancer Society.
BACKGROUND: Clinical testing for BRCA1/2 has been available since 1996. Interest in testing in the research and hypothetical situations has been consistently high, but there have been limited reports on its clinical utilization. METHODS: This is a retrospective study of BRCA1/2 test utilization by high-risk patients who were seen at the Johns Hopkins Breast and Ovarian Surveillance Service. RESULTS: Between February 1996 and December 1999, 258 families who had at least a 10% chance of carrying a BRCA1/2 mutation were offered genetic testing. Of these, 26 families seen between February 1996 and October 1996 had access to free testing. Overall, 68 of 258 (26%) underwent genetic testing. Educational level, number of children or daughters, breast carcinoma screening behavior, smoking and drinking behavior, perceived risk of breast carcinoma, and family history was not associated with test utilization. Eligibility for free testing, prior history of breast or ovarian carcinoma, Ashkenazi Jewish versus non-Ashkenazi Jewish heritage, genetic risk category, and age category were associated with test utilization, and in multivariate analysis, the first three remained statistically significant factors associated with genetic testing. Only 26% of the 50 patients who did not have access to free testing sought insurance reimbursement, of which greater than 50% (7 of 13) had a prior diagnosis of breast or ovarian carcinoma. CONCLUSIONS: The actual utilization of BRCA1/2 genetic testing in a clinical setting is lower than in the research and hypothetical settings. Potential obstacles include cost, fear of insurance discrimination, and need to involve an affected family member in the testing process. Copyright 2002 American Cancer Society.
Authors: Larissa A Meyer; Meaghan E Anderson; Robin A Lacour; Anuj Suri; Molly S Daniels; Diana L Urbauer; Graciela M Nogueras-Gonzalez; Kathleen M Schmeler; David M Gershenson; Karen H Lu Journal: Obstet Gynecol Date: 2010-05 Impact factor: 7.661
Authors: Sherry I Brandt-Rauf; Victoria H Raveis; Nathan F Drummond; Jill A Conte; Sheila M Rothman Journal: Am J Public Health Date: 2006-10-03 Impact factor: 9.308
Authors: Anita Yeomans Kinney; Sara Ellis Simonsen; Bonnie Jeanne Baty; Diptasri Mandal; Susan L Neuhausen; Kate Seggar; Rich Holubkov; Ken Smith Journal: Am J Med Genet A Date: 2006-04-15 Impact factor: 2.802
Authors: Reshma Jagsi; Kent A Griffith; Allison W Kurian; Monica Morrow; Ann S Hamilton; John J Graff; Steven J Katz; Sarah T Hawley Journal: J Clin Oncol Date: 2015-04-06 Impact factor: 44.544
Authors: Kimberly M Kelly; Lee Ellington; Nancy Schoenberg; Parul Agarwal; Thomas Jackson; Stephanie Dickinson; Jame Abraham; Electra D Paskett; Howard Leventhal; Michael Andrykowski Journal: J Genet Couns Date: 2014-03-28 Impact factor: 2.537
Authors: Li Rita Zhang; Anna M Chiarelli; Gord Glendon; Lucia Mirea; Sarah Edwards; Julia A Knight; Irene L Andrulis; Paul Ritvo Journal: Eur J Cancer Prev Date: 2011-07 Impact factor: 2.497